Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2016
17th World Conference on Lung Cancer
Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria
Presentation Date(s):- Dec 4 - 7, 2016
- Total Presentations: 2466
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
PL03 - Presidential Symposium
- Type: Plenary
- Track:
- Presentations: 10
- Moderators:D.P. Carbone
- Coordinates: 12/06/2016, 08:35 - 10:25, Hall D (Plenary Hall)
-
+
PL03.03 - Randomised Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3) (Abstract under Embargo until December 6, 7:00 CET)
09:05 - 09:15 | Author(s): V. Papadimitrakopoulou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
PR03 - Press Conference: Accurate Diagnosis
- Type: Press Conference
- Track:
- Presentations: 4
- Moderators:T. Mok
- Coordinates: 12/06/2016, 10:30 - 11:45, Schubert 1
-
+
PR03.02 - Randomised Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3)
10:30 - 10:30 | Author(s): V. Papadimitrakopoulou
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MA08 - Treatment Monitoring in Advanced NSCLC
- Type: Mini Oral Session
- Track: Advanced NSCLC
- Presentations: 12
- Moderators:R. Perez-Soler
- Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 3-4
-
+
MA08.03 - Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis
11:12 - 11:18 | Author(s): Y.-. Wu
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA10 - EGFR Mutations
- Type: Oral Session
- Track: Biology/Pathology
- Presentations: 8
- Moderators:J. Spicer
- Coordinates: 12/06/2016, 11:00 - 12:30, Strauss 1
-
+
OA10.01 - Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade
11:00 - 11:10 | Author(s): J.W. Riess
- Abstract
Loading... -
+
OA10.03 - YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer
11:20 - 11:30 | Author(s): R. Rosell
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.06 - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Scientific Co-Operation/Research Groups (Clinical Trials in Progress should be submitted in this category)
- Presentations: 47
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.06-005 - Phase 1 Study of Ramucirumab or Necitumumab in Combination with Osimertinib (AZD9291) in Advanced T790M-Positive EGFR-Mutant NSCLC
14:30 - 14:30 | Author(s): D. Planchard
- Abstract
Loading...
-
+
MA16 - Novel Strategies in Targeted Therapy
- Type: Mini Oral Session
- Track: Chemotherapy/Targeted Therapy/Immunotherapy
- Presentations: 12
- Moderators:G. Purkalne
- Coordinates: 12/07/2016, 14:20 - 15:50, Strauss 2
-
+
MA16.11 - CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials
15:26 - 15:32 | Author(s): G. Goss
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.02b - Poster Session with Presenters Present
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 126
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-032 - Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC
14:30 - 14:30 | Author(s): A. Buder
- Abstract
Loading... -
+
P3.02b-077 - Osimertinib Expanded Access Program for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC
14:30 - 14:30 | Author(s): E.S. Santos
- Abstract
Loading... -
+
P3.02b-080 - Analysis of Patient-Reported Symptom Response with Osimertinib (AZD9291) Treatment for Advanced Non-Small-Cell Lung Cancer
14:30 - 14:30 | Author(s): S. Novello
- Abstract
Loading... -
+
P3.02b-092 - Central Nervous System (CNS) Responses to Osimertinib in Brain Metastases from Lung Cancer (NSCLC) with T790M: Effectiveness of the 80 Mg Dose
14:30 - 14:30 | Author(s): W. Park
- Abstract
Loading... -
+
P3.02b-096 - Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results
14:30 - 14:30 | Author(s): C. Zhou
- Abstract
Loading... -
+
P3.02b-099 - Pharmacokinetics of Osimertinib (AZD9291) in Chinese Patients with Advanced NSCLC: A Phase I Study
14:30 - 14:30 | Author(s): J. Cao
- Abstract
Loading... -
+
P3.02b-101 - EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib
14:30 - 14:30 | Author(s): M.J. Hochmair
- Abstract
Loading... -
+
P3.02b-102 - Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
14:30 - 14:30 | Author(s): J. Remon
- Abstract
Loading... -
+
P3.02b-106 - Local Experience of Osimertinib Use; Retrospective Review Based on Plasma EGFR Using ddPCR Technique
14:30 - 14:30 | Author(s): J.Y.C. Li
- Abstract
Loading... -
+
P3.02b-113 - Clinical Course of NSCLC Patients with EGFR Mutation Undergoing Rebiopsy and Osimertinib Therapy
14:30 - 14:30 | Author(s): K. Hirai
- Abstract
Loading... -
+
P3.02b-115 - Clinical Activity of Osimertinib in EGFR Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib
14:30 - 14:30 | Author(s): S.M. Gadgeel
- Abstract
Loading... -
+
P3.02b-119 - YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC
14:30 - 14:30 | Author(s): M.H. Hong
- Abstract
Loading... -
+
P3.02b-124 - Efficacy of Osimertinib in Patients with Non-Small-Cell Lung Cancer (NSCLC) and Pleural Effusion
14:30 - 14:30 | Author(s): S. Manabe
- Abstract
Loading...
